Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundInfluentialThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676 · cited 7×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and 2.3.2.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“All other disease characteristics, such as the formation of NFTs out of hyperphosphorylated tau, and neurodegeneration, are seen a result of this accumulation [12,83,88].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“This statement is further underlined by the hypothetical model of dynamic biomarkers [77,78].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Items 101–200 of 351
Chang, H., Hsu, S., Kao, Z.-K., Lee, C., Huang, S., Lin, C.-H., Liu, M., & Chang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314635 · Cited by 10
Gao, N., Liu, Z., Deng, Y., Chen, H., Ye, C., Yang, Q., & Ma, T. (2023) · Human Brain Mapping · doi:10.1002/hbm.26460 · Cited by 10
Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 9
Ageing, Neurodegeneration and the Endocannabinoid System
Fernández‐Ruíz, J., Sagredo, O., Gómez‐Ruíz, M., & de Lago, E. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_597 · Cited by 9
Detection and Classification of Alzheimer’s Disease Using Deep and Machine Learning
Khalid, M., Iqbal, N., Ali, B., Rahman, J. S. U., Iqbal, S., Almudaimeegh, L., Hamd, Z. Y., & Gareeballah, A. (2025) · Tomography · doi:10.3390/tomography12010004 · Cited by 10
“Such patterns can help deep learning models to distinguish between healthy aging, MCI, and AD, providing the possibility of a scalable and objective staging of diseases [12,35,36].”
Dysfunction of olfactory structures: A conserved mechanism of neurodegeneration?
Jiménez, A., Organista‐Juárez, D., Rocha, L., Estudillo, E., Fernández-Sánchez, V., Cureño-Díaz, M. A., Guzmán‐Ruiz, M. A., & Guevara‐Guzmán, R. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100053 · Cited by 9
Quantitative magnetic resonance imaging in Alzheimer’s disease: a narrative review
Malhi, B. S., Lo, J., Toto‐Brocchi, M., Avval, A. H., Ma, Y., & Du, J. (2025) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-1602 · Cited by 9
“Cerebral atrophy in the antemortem brain appears to be the strongest indicator of underlying AD neuropathology along with other incidental neurodegenerative findings such as HS and TDP-43 encephalopathy (8,24).”
Mild Behavioral Impairment and Cortical Thinning: Biomarkers of Early Neurodegeneration
Leow, Y. J., Saffari, S. E., Vipin, A., Tanoto, P., Salim, R., Qiu, B., Ismail, Z., & Kandiah, N. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.06.010 · Cited by 9
Influence of cerebral blood flow on volumetric loss related to Alzheimer’s disease
Agnollitto, M. I. S. S., Leoni, R. F., Foss, M. P., Palaretti, J., Cayres, M., Pansarim, V., Nather, J. C., Zotin, M. C. Z., Ferrioli, E., Lima, N. K. D. C., et al. (2023) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2023-0004 · Cited by 9
Alqubati, G. M. F., & Algaphari, G. H. (2021) · International Journal of Computer Systems & Software Engineering · doi:10.15282/ijsecs.7.2.2021.4.0087 · Cited by 9
“…techniques used to support doctors’ diagnosis of AD and help measure the size of degeneration of some brain areas that can lead to early detection [31]. sMRI scans , shown in Fig 3, produce high contrast images used to measure the volume of the grey and white matter of the patient's brain [32].”
MethodLiu, R., Li, G., Gao, M., Cai, W., & Ning, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.916020 · Cited by 9
Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease
Chen, W., Zhang, T., & Zhang, H. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137816 · Cited by 8
Yang, H. J., Dong, C., Cai, Y., Zhao, M., Liu, J., Bian, S., & Ding, X. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1596459 · Cited by 8
Hu, W., Du, Q., Wei, L., Wang, D., & Zhang, G. (2025) · European journal of medical research · doi:10.1186/s40001-025-03204-z · Cited by 8
“Sub-tle hippocampal changes may be difficult to delineate visually, particularly in preclinical or early symptomatic phases (9–11).”
Guelib, B., Bounab, R., Aliouane, S. E., Hermessi, H., Khlifa, N., & Zarour, K. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.112307 · Cited by 8
Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer's disease
Zhuang, T., Yang, Y., Ren, H., Zhang, H., Gao, C. Q., Chen, S., Shen, J., Ji, M., & Cui, Y. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105650 · Cited by 8
“…at high risk for developing AD through the utilization of biomarker-based predictive models, following interventions targeting potential risk factors, holds promising potential to control the incidence of the disease (Zhang et al., 2021, Graff-Radford et al., 2021, van Oostveen & de Lange, 2021).”
InfluentialLi, F., Cheng, J., Jin, K., Zhao, L., Li, J., Wu, J., & Ren, X. (2024) · Brain and Behavior · doi:10.1002/brb3.70111 · Cited by 7
“A β PET or MRI—depends on factors like the clinical situation, availability of technology, and physician preference (van Oostveen and de Lange 2021; Kim et al. 2022).”
BackgroundPederzoli, V., Corti, M., Riccobelli, D., & Antonietti, P. F. (2025) · Computer Methods in Applied Mechanics and Engineering · doi:10.1016/j.cma.2025.118118 · Cited by 8
Recent diagnostic techniques for the detection of Alzheimer’s disease: a short review
Bhujbal, S. S., Kad, M. M., & Patole, V. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03244-y · Cited by 8
Rudisch, D. M., Krasko, M. N., Barnett, D. G. S., Mueller, K. D., Russell, J. A., Connor, N. P., & Ciucci, M. R. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1294648 · Cited by 8
Guo, Y., Hu, Z., & Wang, Z. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.778955 · Cited by 8
Saha, R., Mukherjee, A., Bal, A., Chakrabarti, A., & Mandal, S. N. (2025) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-025-10702-z · Cited by 7
Lee, E. B., Hwang, J., Kim, D. W., Choi, B. Y., Bae, H., Won, S., Park, Y. H., & Kim, S. (2025) · BMC Neurology · doi:10.1186/s12883-025-04583-w · Cited by 182
“…represents a small, focal cortical structure and is therefore sensitive to subtle thinning [22], whereas hippocampal volume is a more variable metric that is strongly influenced by age, intracranial volume, vascular factors, lifestyle factors, and other nonspecific sources of variability [75, 76].”
AI agents in Alzheimer’s disease management: challenges and future directions
Grammenos, G., Vrahatis, A. G., Lazaros, K., Exarchos, T. P., Vlamos, P., & Krokidis, M. G. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1735892 · Cited by 8
Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes
Su, F., Kim, W. S., Halliday, G. M., & Fu, Y. (2026) · Cells · doi:10.3390/cells15050451 · Cited by 7
“Integrating complementary biomarkers [265,266] within a network-aligned framework that reflects cell-type dysfunctions enables more accurate disease assessment and more refined patient stratification.”
Implantable Intraocular Fluorescence Sensor for Visualized Monitoring of Alzheimer's Disease
Lim, J., Lee, H. J., Kim, J., Moon, C., Lee, J., Kang, Y., Kim, R., Mun, B., Ji, Y. W., & Haam, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202413723 · Cited by 7
Habiba, S. U., Choi, H. J., Munni, Y. A., Yang, I., Haque, M. N., & Moon, I. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312701 · Cited by 7
“The seeds were carefully selected by an expert to ensure their suitability for use in hippocampal culture experiments.”
Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease
Ozturk, B., Demir, H., Silindir‐Gunay, M., Akdağ, Y., Şahin, S., & Gülsün, T. (2025) · Current Neuropharmacology · doi:10.2174/011570159x370790250317045223 · Cited by 8
D’Alessandro, T., Stefano, C. D., Fontanella, F., Nardone, E., & Pace, C. D. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-70536-6_20 · Cited by 7
B., V., Alazzam, M. B., Ahmed, H. S., Sharif, S. F. A., Hassan, Z. H., & Saravanakumar, R. (2025) · International Conference on Engineering Innovations and Technologies (ICoEIT) · doi:10.1109/icoeit63558.2025.11211573 · Cited by 6
APOE4-related differences in cortical thickness are modulated by sex in middle age
Leclaire, K. N., Blujus, J. K., Korthauer, L. E., & Driscoll, I. F. (2024) · Brain Imaging and Behavior · doi:10.1007/s11682-024-00911-9 · Cited by 6
“Notably, much of our knowledge regarding structural brain integrity is based on region-specific volumetric studies, though volume loss is not an AD-specific measure (van Oostveen & de Lange, 2021).”
Mushtaq, M., Khan, M. A., Hussain, Z., Ayouni, S., Maddeh, M., & Alhayan, F. (2025) · Cognitive Computation · doi:10.1007/s12559-025-10505-2 · Cited by 6
The Future of Artificial Intelligence for Alzheimer’s Disease Diagnostics
Logan, R. A., Zerbey, S. S., & Miller, S. (2021) · Advances in Alzheimer s Disease · doi:10.4236/aad.2021.104005 · Cited by 6
“It has been shown repeatedly that the best defense against neurodegeneration is an early offense, which is only made possible through an early diagnosis [4].”
BackgroundAbedi, A., Foroutan, T., Shalmani, L. M., & Dargahi, L. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109675 · Cited by 6
Yan, D., Xiong, C., Zhong, Q., Yao, Y., Chen, S., Mei, X., & Zhu, S. (2023) · Biomedical Optics Express · doi:10.1364/boe.487939 · Cited by 6
Predictive gene expression signatures for Alzheimer’s disease using post-mortem brain tissue
Duche, A., Tan, O., Baskys, A., Sumbria, R. K., & Roosan, M. R. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1591946 · Cited by 6
A systematic review of brain health in adults with chronic pain
Lee, A. H. Y., Al‐Dahwi, S., Angell, T., Arulalagan, A., Bloxsom, R., Clarkson, H., Faure, R., Goodarzi, S., Gupta, M., Kale, A., et al. (2025) · Anaesthesia · doi:10.1111/anae.70021 · Cited by 5
Barba, T., Bagley, B. A., Steyaert, S., Carrillo‐Pérez, F., Sadée, C., Iv, M., & Gevaert, O. (2025) · GigaScience · doi:10.1093/gigascience/giaf116 · Cited by 5
“In this setting, magnetic resonance imaging (MRI) has established it as a fundamental tool in the diagnosis and surveillance of cancers, neurodegenerative disorders, and inflammatory diseases of the central nervous system [ 5 , 6 ].”
Corrao, S., Scibetta, S., Pardo, N., Cangemi, I., Mirarchi, L., Corrao, G., Amodeo, S., & Calvo, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1668159 · Cited by 5
How gut microbiota contribute to neuropsychiatric disorders: evidence from neuroimaging studies
Jia, C., Zhu, W., Yu, Y., & Xie, Q. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1760096 · Cited by 5
“Furthermore, multimodal imaging techniques like MRI and PET, combined with microbial metabolite data, hold promise for developing comprehensive biomarkers for precise diagnosis and longitudinal efficacy monitoring (van Oostveen and de Lange, 2021).”
Petrov, W., Ślebioda, D., Kozińska, R. B., Kukla, K., Petrov, P., Sroka, M., Tesyna, J., Puźniak, G., Kudliński, M., Rejda, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135733 · Cited by 6
“This pathology develops insidiously—neuronal loss and synaptic dysfunction may occur even a dozen or so years before the first observable deficits become apparent [4].”
Gao, N., Ye, C., Chen, H., Hao, X., & Ma, T. (2024) · Human Brain Mapping · doi:10.1002/hbm.26715 · Cited by 5
“Right: slices corresponding to the cutting orientations shown in the left panel. hippocampus has limited specificity in distinguishing the AD converters and the non-converters (Lombardi et al., 2020; Ruchinskas et al., 2022; van Oostveen & de Lange, 2021).”
BackgroundZhai, T., Qian, W. P., Paulus, Y. M., Wang, X., & Zhang, W. (2024) · Biomedical Optics Express · doi:10.1364/boe.532042 · Cited by 5
“However, the invasiveness of CSF test and the high cost and limited access associated with PET pose considerable challenges for screening larger populations and predicting the progression of AD [11].”
Cui, X., Li, M., Lei, G., Wang, J., Pan, J., Zhu, S., Wu, T., Zou, L., & Yan, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1453051 · Cited by 5
Preprocessing Techniques for Neuroimaging Modalities: An In-Depth Analysis
Joseph, A., & Jayaraman, C. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109803 · Cited by 5
Co-twin design in brain imaging—review on biomarkers of Alzheimer's disease
Varjonen, A., Schwarz, C., & Vuoksimaa, E. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad181 · Cited by 6
Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 5
Zhang, B., Xu, M., Wu, Q. H., Ye, S., Zhang, Y., Li, Z., & Initiative, A. D. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1328301 · Cited by 5
“However, the current classification or prediction of conversion for MCI leaves much to be desired (van Oostveen and de Lange, 2021).”
BackgroundMahajan, G., Pandya, K., Tripathi, A., & Kumar, D. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108949 · Cited by 4
Wang, N., Shen, X., Huang, H., Zhao, R., Jiwa, H., Li, Z., Li, P., Ye, J., & Zhou, Q. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101317 · Cited by 4
Numerical Modelling of Protein Misfolding in Neurodegenerative Diseases: A Computational Study
Antonietti, P. F., & Corti, M. (2025) · Lecture notes in computational science and engineering · doi:10.1007/978-3-031-86173-4_1 · Cited by 4
“However, due to the existence of many different pathologies linked to this prionic protein, there is intense research on the construction of significant biomarkers both from the analysis of biofluid (cerebrospinal fluid and blood) and the study of different types of medical images [5].”
BackgroundLee, H. J., Lim, J., Shin, M., Moon, C., Lee, J., Kim, J., Kang, Y., Ji, Y. W., & Haam, S. (2024) · Small Structures · doi:10.1002/sstr.202400154 · Cited by 4
Edukasi untuk Deteksi Dini dan Perawatan Lansia dengan Alzheimer di Masa Pandemi Covid-19
Nurbaiti, N., Sutoro, S. G., Supriyaningsih, E., Wiyanti, S. W., & Maesaroh, I. (2023) · JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM) · doi:10.33024/jkpm.v6i7.10093 · Cited by 4
Akbarifar, A., Maghsoudpour, A., Mohammadian, F., Mohammadzaheri, M., & Ghaemi, O. (2024) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-024-05367-w · Cited by 4
Early Detection of Alzheimer's disease by using the Latest TechniquesPreprint
Ahmad, S., Aijaz, M., Ahmad, M., Hafeez, A., Asif, M., Kumar, A., Al‐Taie, A., & Ansari, M. A. (2023) · doi:10.22541/essoar.168056798.85734608/v1 · Cited by 4
Predicting Alzheimer’s Disease Progression from Sparse Multimodal Data by NeuralODE ModelsPreprint
Zanin, A., Pagani, S., Corti, M., Crepaldi, V., Fede, G. D., Antonietti, P. F., & the Alzheimer’s Disease Neuroimaging Initiative, A. D. N. I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672412 · Cited by 4
Detecting mild cognitive impairment by applying integrated random forest to finger tapping
Sano, Y., Suzumura, S., Sugioka, J., Mizuguchi, T., Kandori, A., & Kondo, I. (2025) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-025-03306-0 · Cited by 3
“For early detection, methods such as blood testing [5, 25], cerebrospinal fluid (CSF) biomarkers [1, 2, 33], magnetic resonance imaging (MRI) [11, 43], single-photon emission computed tomography (SPECT) [10, 46], and positron emission tomography (PET) [29, 43] have been used.”
AI-Enhanced Imaging Techniques for Understanding Alzheimer's Progression
Chaudhari, A., Saratkar, S., & Thute, T. (2025) · International Conference on Machine Learning and Autonomous Systems (ICMLAS) · doi:10.1109/icmlas64557.2025.10969042 · Cited by 3
“Machine learning systems can detect profiles of brain atrophy or metabolic decline in different areas and indicate exactly how the disease progresses in individual patients and how it is better to adjust the treatment [11].”
Dey, D., Mukherjee, D. R., Shoeb, A. K. M., Biswas, P., & Santra, S. (2025) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v13i3.929 · Cited by 3
Dar, Z. M., & Muthusamy, C. (2025) · IEEE Access · doi:10.1109/access.2025.3610474 · Cited by 3
“Despite extensive efforts in biomarker development through cerebrospinal fluid analysis and neuro-imaging [5], the underlying mechanisms governing tau misfolding and propagation remain elusive.”
Hechkel, W., Leo, M., Carcagnì, P., Coco, M. D., & Helali, A. (2026) · Information · doi:10.3390/info17020163 · Cited by 3
Metallospecies and their biological functions in Alzheimer’s disease
Pereira, M. V. S., & de Jesus, J. R. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.005 · Cited by 3
Singh, S., Sharma, Y., Bhardwaj, P., Kothari, D., Chhikara, A., Gupta, V., Kumar, D., Choudhary, N., & Kondaveeti, S. B. (2026) · Behavioral and Brain Functions · doi:10.1186/s12993-026-00329-x · Cited by 3
Arachchige, A. S. P. M., Schmiliver, B., & Alves, G. A. M. (2026) · AIMS neuroscience · doi:10.3934/neuroscience.2026009 · Cited by 3
Application of Machine Learning for Image Processing in the Healthcare Sector
Priya, N., Satpathy, I., & Patnaik, B. C. M. (2023) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-0876-9.ch004 · Cited by 3
Multi-view k-Nearest Neighbor Graph Contrastive Learning on Multi-modal Biomedical Data
Zhang, Y., Chen, S., McCoy, R. G., Chen, C., & Chen, Y. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-66535-6_26 · Cited by 3
Impaired Striatum Dopamine Release in Parkinson’s Disease
Adam, H., Gopinath, S. C. B., Adam, T., Salim, E. T., & Fakhri, M. A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673356301250130074521 · Cited by 3
Taheri, S., Paknejadi, M., Esmaeili, D., Ferdousi, A., & Shahhosseiny, M. H. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138192 · Cited by 3
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Zhan, Y., Zuo, F., Zhang, Z., Wu, X., Dai, Y., Jiao, T., Shi, Q., Wang, Z., & Zhang, G. (2025) · Journal of Visualized Experiments · doi:10.3791/67574 · Cited by 3
Yuan, R., Cai, J., Cen, Y., Zou, G., Xu, Y., Ma, X., & Su, S. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114018 · Cited by 3
Yang, W., Ye, Y., Cai, Y., Wang, G., Wang, M., & Zhang, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4311031 · Cited by 3
“By reviewing the literature [15, 16], the diagnostic criteria for perimenopausal MCI of the kidney deficiency and blood stasis type were developed: (i) women aged 40–60 years; (ii) main symptoms: forgetfulness and memory loss; (iii) secondary symptoms: soreness and weakness of the waist and knees, tiredness and sleepi…”
MethodLin, H., Tang, S., Liang, L., Chen, L., Zou, C., & Zou, D. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3039248 · Cited by 3
“The widespread use of CSF- and PET-based imaging biomarkers remains limited due to the perceived invasive nature of lumbar puncture and the high cost and low availability of PET imaging [12, 14].”
BackgroundMethodRetractedmazrooei, E., Dastury, M. R., & Zendehbad, S. A. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.12.3.91 · Cited by 3
Investigating Neurodegenerative Diseases From Alzheimer's to Parkinson's
Khare, N., Khare, P., & Priyadarshi, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-5464-3.ch015 · Cited by 3
Graphene Chemeo‐Phononics for Biosensor Applications: An Interfacial Raman Transducer
Keisham, B., Kim, S., Cotts, S., & Berry, V. (2022) · Advanced Materials Interfaces · doi:10.1002/admi.202200773 · Cited by 3
Gholampour, M., Seradj, H., & Sakhteman, A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00038 · Cited by 3
Facile synthesis of stilbene-derivatized Schiff base ligands and their Cu(II) complexes
Uehara, D., & Salas, P. F. (2023) · Tetrahedron Letters · doi:10.1016/j.tetlet.2023.154406 · Cited by 3
Hải, N. T., Huynh, T., Nguyen, M., Nguyen, H., Bui, L. C., Ta, T. M., Nguyen, H. X., & Ha, H. (2024) · Brain Science Advances · doi:10.26599/bsa.2024.9050009 · Cited by 2
“…phosphorylated tau proteins [9]; (2) structural neuroimaging, such as brain MRI and volumetric measurements of structures such as the hippocampus [10]; and (3) functional neuroimaging, including metabolic studies with fluorodeoxyglucose ‐ positron emission tomography (PET) and protein labeling…”
Vicini, M., Folegati, P., Ferragut, R., & Conci, C. (2025) · Diffusion and defect data, solid state data. Part B, Solid state phenomena/Solid state phenomena · doi:10.4028/p-wjwi48 · Cited by 2
“Thus, while valuable for diagnosis, it does not effectively offer preventative insight or specificity for Alzheimer’s disease [9].”
Alattar, A. A., Bartek, J. J., Chuck, C. C., Kozel, G., Wang, E. J., Chen, H.-C., Sanghvi, P. R., Wong, E. T., Sarangi, S., Elinzano, H., et al. (2025) · Clinical & Experimental Metastasis · doi:10.1007/s10585-025-10370-1 · Cited by 2
Classification of HC, MCI, and AD Based on CT Using Deep Learning
Hsiao, I., Lin, K., Chang, C.-C., & Huang, H. (2025) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-025-00985-w · Cited by 2
Deshpande, S., & Kulkarni, N. (2026) · IEEE Access · doi:10.1109/access.2026.3658101 · Cited by 2
“Similarly, DenseNet networks emphasize dense connectivity between layers, improving feature reuse and gradient flow an advantage when working with smaller or imbalanced medical datasets [16].”
Wang, X., Tong, J., Wang, M., Du, B., Wang, H., Liu, H., Yang, X., Mu, R., Wang, K., Liu, X., et al. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.119030 · Cited by 2
Lv, X. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105340 · Cited by 2
Embedded Gene Expression Data Based On RidgeClassifier For Alzheimer’s Disease Classification
Guelib, B., Khlifa, N., & Bounab, R. (2023) · International Conference on Innovations in Intelligent Systems and Applications (INISTA) · doi:10.1109/inista59065.2023.10310317 · Cited by 2
Shen, G., Ye, F., Cheng, W., & Li, Q. (2024) · BioMedical Engineering OnLine · doi:10.1186/s12938-024-01305-0 · Cited by 2
Clinical practice guidelines for assessment and management of mild neurocognitive disorder
Subramanyam, A. A., Singh, S., & Raut, N. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_693_24 · Cited by 2
Radiomics features of FDG PET images predict ApoE4
Rasi, R., & Güveniş, A. (2025) · European Journal of Radiology Artificial Intelligence · doi:10.1016/j.ejrai.2025.100009 · Cited by 2
Andersen, A. B. A., Lehel, S., Grove, E. K., Langkjær, N., Fuglø, D., & Huynh, T. H. V. (2024) · Pharmaceuticals · doi:10.3390/ph17020217 · Cited by 2
“N -[ 11 C]methylaminophenyl)-6-hydroxybenzothiazole ([ 11 C]6-OH-BTA-1), also known as [ 11 C]Pittsburg Compound B ([ 11 C]PiB, Figure 1), is used for early diagnosis of Alzheimer’s disease (AD) by positron emission tomography (PET) [1,2].”
BackgroundMethodInfluentialMahdy, S., & Abuelmakarem, H. S. (2024) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.3816 · Cited by 2
Manuskandan, S. R., & Anandh, K. R. (2021) · IEEE Signal Processing in Medicine and Biology Symposium · doi:10.1109/spmb52430.2021.9672297 · Cited by 2
Predicting dementia progression with fully connected cascade neural networksPreprint
Akbarifar, A., Maghsoudpour, A., Mohammadian, F., Mohammadzaheri, M., & Ghaemi, O. (2024) · Research Square · doi:10.21203/rs.3.rs-4115962/v1 · Cited by 2
AAV-mediated expression of Secreted Klotho as a therapeutic strategy for Alzheimer's disease
Blanch, R. (2023) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) · Cited by 2
Kaur, K. (2022) · Nottingham ePrints (University of Nottingham) · Cited by 2
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1
Rajeswari, S., & Swathi, K. (2025) · Journal of Innovative Image Processing · doi:10.36548/jiip.2025.2.009 · Cited by 1
Wu, J., Zhang, Z., Pulgar, I. M. R., Jiang, S., Wang, P., Chai, K., Pathak, A. P., Oishi, K., Li, Y., Bang, J., et al. (2025) · Magnetic Resonance in Medicine · doi:10.1002/mrm.70122 · Cited by 1
“PET is currently the most useful neuroimaging tool for in vivo detection of these pathological hallmarks of AD [58–60].”
An Aggregation‐Induced Emission Fluorescent Probe for Detecting β‐Amyloid Plaques
Liu, B., Yuan, L., Liu, S., Zhang, X., Liu, F., Xin, W., Wang, S., Ba, X., & Zhang, Y. (2025) · ChemistrySelect · doi:10.1002/slct.202503358 · Cited by 1
Machine learning models of Alzheimer's disease spectrum using blood tests
Falasca, N. W., Ferretti, A., Granzotto, A., Sensi, S. L., Franciotti, R., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70228 · Cited by 1
Early Detection of Alzheimer’s Disease Using Deep Learning and SMOTE for Class Imbalance Correction
Banerjee, J., Saha, S., Gupta, P., & Chandra, A. (2026) · Lecture notes in networks and systems · doi:10.1007/978-981-96-8309-3_33 · Cited by 1
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.